Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 12;9(7):e3668.
doi: 10.1097/GOX.0000000000003668. eCollection 2021 Jul.

Best Clinical Practices with ATX-101 for Submental Fat Reduction: Patient-related Factors and Physician Considerations

Craig F Teller  1 , Annie Chiu  2 , Cameron D Chesnut  3   4 , Deborah Sherman  5 , José Raul Montes  6   7 , Sara Gaspard  8 , Terrence Keaney  9 , Neil S Sadick  10 , Steve Yoelin  11 , Sara Sangha  12 , Sachin M Shridharani  13
Affiliations

Best Clinical Practices with ATX-101 for Submental Fat Reduction: Patient-related Factors and Physician Considerations

Craig F Teller et al. Plast Reconstr Surg Glob Open. .

Abstract

Background: Submental fat can be reduced with ATX-101 (deoxycholic acid injection), a customizable and minimally invasive alternative to liposuction. In the years since its approval, the treatment patterns of ATX-101 have evolved.

Methods: A panel of experienced physicians from the United States gathered to generate best practices for the use of ATX-101 in submental contouring.

Results: The expert panel provided their insights on appropriate patient selection, managing patient expectations of ATX-101 treatment outcomes, and adverse events, and guidance on ATX-101 administration for optimal outcomes are presented here.

Conclusion: These best clinical practices on the use of ATX-101 for the reduction of submental fat should enable physicians to enhance the patient treatment experience and outcomes.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Dr Teller is a consultant and investigator for Allergan Aesthetics, an AbbVie Company. Dr Chiu is a consultant, speaker, investigator, and trainer for Allergan Aesthetics, an AbbVie Company, as well as a consultant and speaker for Merz, Cynosure, BTL, Endo, and Revance. Dr Chesnut is a consultant for Allergan Aesthetics, an AbbVie Company, and Galderma and participates in the speaker’s bureau for Allergan Aesthetics, an AbbVie Company and Galderma. Dr Sherman is an advisory board member for Allergan Aesthetics, an AbbVie Company. Dr Montes is an advisory board member for Allergan Aesthetics, an AbbVie Company and a speaker and trainer for Allergan Aesthetics, an AbbVie Company, Galderma, and Merz. Dr Gaspard is an advisory board member for Allergan Aesthetics, an AbbVie Company. Dr Keaney is a consultant for Allergan Aesthetics, an AbbVie Company and Unilever. Dr Sadick is a consultant for Allergan Aesthetics, an AbbVie Company, Almirall, Venus Concept, Cynosure, Endo, Eternogen, Gerson Lehrman Group, Merz Aesthetics, and Valeant; an investigator for Amgen, Cassiopea SpA, Celgene Corporation, Cutera, Inc., Cyosure, Inc., DS Laboratories, Eli Lilly and Company, Endo, Foamix, Galderma, Hydropeptide, Kadmon Corp, LEO Laboratories Ltd, Neostrata, Novartis, Nutratceutical Wellness, Pfizer, Ralexar Therapeutics, Regeneron, Roche, Valeant, Vanda Pharma, Venus Concept. Dr Yoelin is a consultant for Allergan Aesthetics, an AbbVie Company and received a research grant from Allergan Aesthetics, an AbbVie Company. Dr Sangha is an employee and stockholder of AbbVie. Dr Shridharani is an advisory board member for Allergan Aesthetics, an AbbVie Company, Galderma, Merz, and Sientra.

Figures

Fig. 1.
Fig. 1.
Representative before/after treatment photographs of a 31-year-old patient with mild submental fat at baseline who received one 8-mL treatment of ATX-101. Time between before and after photographs was 2 months, 5 days. Photos courtesy of Sachin M. Shridharani, MD.
Fig. 2.
Fig. 2.
Representative before and after treatment photographs of a 58-year-old patient with moderate submental fat at baseline who received two ATX-101 treatments (total combined volume, 20 mL). Time between last treatment and after photograph was 3 months, 13 days. Photos courtesy of Sachin M. Shridharani, MD.
Fig. 3.
Fig. 3.
Representative photographs of typical swelling 1 day, 1 week, and 4 weeks after ATX-101 treatment. At baseline, patient was 43 years old, weighed 149.2 lb, and had a body mass index of 25.6 kg/m2.
Fig. 4.
Fig. 4.
ATX-101 treatment area and injection pattern, as shown in the Kybella (deoxycholic acid) injection prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206333s002s003lbl.pdf. Kybella [package insert]. Irvine, Calif.: Allergan Sales, LLC. 2015. Used with permission.
See this image and copyright information in PMC

References

    1. Rohrich RJ, Rios JL, Smith PD, et al. . Neck rejuvenation revisited. Plast Reconstr Surg. 2006; 118:1251–1263. - PubMed
    1. Baumann L, Shridharani SM, Humphrey S, et al. . Personal (self) perceptions of submental fat among adults in the United States. Dermatol Surg. 2019; 45:124–130. - PMC - PubMed
    1. American Society for Dermatologic Surgery. 2017 ASDS consumer survey on cosmetic dermatologic procedures. Available at https://www.asds.net/Medical-Professionals/Practice-Resources/ASDS-Consu.... Accessed September 16, 2019.
    1. Schlessinger J, Weiss SR, Jewell M, et al. . Perceptions and practices in submental fat treatment: a survey of physicians and patients. Skinmed. 2013; 11:27–31. - PubMed
    1. Koehler J. Complications of neck liposuction and submentoplasty. Oral Maxillofac Surg Clin North Am. 2009; 21:43–52. - PubMed

LinkOut - more resources